LGALS8 and pulmonary arterial hypertension: To investigate whether I-BET controls LGALS8 and PAH in vivo, I-BET was intraperitoneally administered daily in two separate models of group 1 PAH in rats—monocrotaline (MCT) exposure followed by 26 days in normoxia and SU5416-hypoxia exposure (3 weeks, days 0 to 21) followed by 2 weeks of normoxia (days 21 to 35).